Eli Lilly, the US pharmaceutical giant behind weight-loss drugs like Zepbound and Mounjaro, has announced a strategic ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

England’s National Health Service (NHS) has proposed a phased launch of Eli Lilly’s blockbuster weight loss drug Mounjaro (tirzepatide) because of the large number of patients who could ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

The Food and Drug Administration said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding ...